Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRADY CORPBRC · Entity 78 | Director | February 22, 2021 | February 23, 2021 |
| PLx Pharma Inc.PLXP · Entity 129056 | Director | February 22, 2022 | February 24, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRADY CORP
Report date February 22, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 13,298 |
Ending reported balance
After 2021-02-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-22 · Exercise / conversion · Acquired 4,250 · Balance 15,564 F1: Represents net exercise of stock option. 4,250 options were exercised, resulting in a net gain of 1,984 shares. Row 2 · 2021-02-22 · Tax withholding · Disposed 2,266 · Balance 13,298 F1: Represents net exercise of stock option. 4,250 options were exercised, resulting in a net gain of 1,984 shares. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2021-09-30 | Direct | 0 |
Reported balance
After 2021-02-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-22 · Exercise / conversion · Disposed 4,250 · Balance 0 F2: Represents options exercisable one third each year for the three years subsequent to the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents net exercise of stock option. 4,250 options were exercised, resulting in a net gain of 1,984 shares.
F2: Represents options exercisable one third each year for the three years subsequent to the grant date.
PLx Pharma Inc.
Report date February 22, 2022 · Filed February 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2032-02-22 | Direct | 20,000 |
Reported balance
After 2022-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-22 · Grant · Acquired 20,000 · Balance 20,000 F1: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended. F2: These stock options vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended.
F2: These stock options vest in full on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2022 Filed Feb 24, 2022 20:10 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0000921895-22-000658 · form411577bal_02242022.xml · derivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-22 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended. F2 · derivative.exercise_date: These stock options vest in full on the first anniversary of the grant date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 20:36 UTC | BRADY CORP BRC · Entity 78 | Exercise / conversionStock Option · Derivative | 4,250 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0000746598-21-000027 · wf-form4_161411258341346.xml · derivative · entry 3 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,250 shares Expires 2021-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents options exercisable one third each year for the three years subsequent to the grant date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 20:36 UTC | BRADY CORP BRC · Entity 78 | Tax withholdingClass A Common Stock | 2,266 | $50.64 | $114,750.24 |
DisclosureSEC source: 0000746598-21-000027 · wf-form4_161411258341346.xml · nonDerivative · entry 2 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,298 F1 · shares: Represents net exercise of stock option. 4,250 options were exercised, resulting in a net gain of 1,984 shares. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 20:36 UTC | BRADY CORP BRC · Entity 78 | Exercise / conversionClass A Common Stock | 4,250 | $27.00 | $114,750.00 |
DisclosureSEC source: 0000746598-21-000027 · wf-form4_161411258341346.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents net exercise of stock option. 4,250 options were exercised, resulting in a net gain of 1,984 shares. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 19:30 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0000921895-20-003078 · form411577002bal_11202020.xml · derivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-11-18 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan. F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 18:40 UTC | BRADY CORP BRC · Entity 78 | GrantClass A Common Stock | 2,731 | $39.92 | $109,021.52 |
DisclosureSEC source: 0000746598-20-000186 · wf-form4_160157762916999.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Compensation Disclosed balance after: 22,835 F1 · shares: Reporting owner acquired 2,731 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors. Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:45 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0000921895-20-000899 · form411577002bal_03242020.xml · derivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-03-20 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan. F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:18 UTC | BRADY CORP BRC · Entity 78 | Exercise / conversionStock Option · Derivative | 8,400 | $0.00 Strike: $29.10 | $0.00 |
DisclosureSEC source: 0000746598-20-000027 · wf-form4_158284188452736.xml · derivative · entry 6 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,400 shares Expires 2020-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents options exercisable one third each year for the three years subsequent to the grant date. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:18 UTC | BRADY CORP BRC · Entity 78 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $28.35 | $0.00 |
DisclosureSEC source: 0000746598-20-000027 · wf-form4_158284188452736.xml · derivative · entry 5 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 10,000 shares Expires 2020-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents options exercisable one third each year for the three years subsequent to the grant date. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:18 UTC | BRADY CORP BRC · Entity 78 | Tax withholdingClass A Common Stock | 4,878 | $50.11 | $244,436.58 |
DisclosureSEC source: 0000746598-20-000027 · wf-form4_158284188452736.xml · nonDerivative · entry 4 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,314 F2 · shares: Represents net exercise of stock option. 8,400 options were exercised, resulting in a net gain of 3,522 shares. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:18 UTC | BRADY CORP BRC · Entity 78 | Exercise / conversionClass A Common Stock | 8,400 | $29.10 | $244,440.00 |
DisclosureSEC source: 0000746598-20-000027 · wf-form4_158284188452736.xml · nonDerivative · entry 3 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents net exercise of stock option. 8,400 options were exercised, resulting in a net gain of 3,522 shares. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:18 UTC | BRADY CORP BRC · Entity 78 | Tax withholdingClass A Common Stock | 5,658 | $50.11 | $283,522.38 |
DisclosureSEC source: 0000746598-20-000027 · wf-form4_158284188452736.xml · nonDerivative · entry 2 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,792 F1 · shares: Represents net exercise of stock option. 10,000 options were exercised, resulting in a net gain of 4,342 shares. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:18 UTC | BRADY CORP BRC · Entity 78 | Exercise / conversionClass A Common Stock | 10,000 | $28.35 | $283,500.00 |
DisclosureSEC source: 0000746598-20-000027 · wf-form4_158284188452736.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents net exercise of stock option. 10,000 options were exercised, resulting in a net gain of 4,342 shares. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:00 UTC | BRADY CORP BRC · Entity 78 | GrantClass A Common Stock | 2,017 | $54.05 | $109,018.85 |
DisclosureSEC source: 0000746598-19-000197 · wf-form4_156935520175871.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Compensation Disclosed balance after: 19,758 F1 · shares: Reporting owner acquired 2,017 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors. Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:51 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0000921895-19-000811 · form411577bal_03182019.xml · derivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-14 F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan. F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 19:02 UTC | BRADY CORP BRC · Entity 78 | GrantClass A Common Stock | 2,479 | $43.98 | $109,026.42 |
DisclosureSEC source: 0000746598-18-000149 · wf-form4_153798853368700.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Compensation Disclosed balance after: 17,419 F1 · shares: Reporting owner acquired 2,479 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors. Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 14:13 UTC | BRADY CORP BRC · Entity 78 | GrantClass A Common Stock | 2,579 | $36.85 | $95,036.15 |
DisclosureSEC source: 0000746598-17-000119 · wf-form4_150643516891756.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Compensation Disclosed balance after: 14,615 F1 · shares: Reporting owner acquired 2,579 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors. Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 21:14 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantOptions · Derivative | 9,002 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001144204-17-021377 · v464773_4.xml · derivative · entry 2 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,002 Underlying: Common Stock · 9,002 shares Expires 2025-07-22 F2 · shares: Received in connection with the Merger in exchange for an employee stock option to buy 11,429 shares of PLx Opco Inc. common stock for $9.80 per share. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 21:14 UTC | PLx Pharma Inc. PLXP · Entity 129056 | GrantCommon Stock | 5,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-021377 · v464773_4.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,445 F1 · price: Received in exchange for 6,914 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.). Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 20:52 UTC | BRADY CORP BRC · Entity 78 | GrantClass A Common Stock | 2,704 | $35.14 | $95,018.56 |
DisclosureSEC source: 0000746598-16-000320 · wf-form4_147500951039515.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Deferred Compensation Disclosed balance after: 11,758 F1 · shares: Reporting owner acquired 2,704 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors. Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account. Read SEC document |
| October 03, 2011 Filed Aug 17, 2017 13:49 UTC | BRADY CORP BRC · Entity 78 | GrantClass A Common Stock | 1,450 | $26.43 | $38,323.50 |
DisclosureSEC source: 0000746598-17-000071 · wf-form4_150297778029979.xml · nonDerivative · entry 1 Balkema Gary S. · CIK 0001497486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,450 F1 · shares: Reporting owner acquired 1,450 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.